TRexBio

The key to lasting immune balance lies in understanding how Tregs adapt within tissues. We are proud to share our team’s editorial opening a new Frontiers in Immunology Research Topic: The Role of Tissue-Localized Regulatory T Cells in Health and Disease.    The editorial from Bevin Smith, Principal Scientist, Ali Zarrin, Chief Scientific Officer, and TRex co-founder Diane Mathis of Harvard Medical School introduces a collection of 11 articles that examine how tissue-localized Tregs respond to genetic, epigenetic, and environmental cues to influence inflammation, repair, and disease. The authors describe these cells as active regulators that can restore immune balance or, in some settings, contribute to disruption.   This Research Topic reflects a principle at the core of TRexBio’s work: understanding immune regulation in the tissue context can reveal new ways to achieve lasting remission in inflammatory and autoimmune diseases. Read the articles here: https://lnkd.in/gYev4ptM #Immunology #Tregs #AutoimmuneDisease #TranslationalScience #DeepBiology #NobelPrize #NobelPrizeinMedicine2025

TRexBio is pleased to welcome Travis Coy, MBA who is CFO and Head of Corporate Development at Immunocore to our Board of Directors!

This year’s Nobel Prize in Physiology or Medicine recognizes the discovery of regulatory T cells (Tregs), specialized “security guard” cells that prevent the immune system from attacking the body’s own tissues. The pioneering work of Drs. Shimon Sakaguchi, Mary Brunkow, and Fred Ramsdell revealed how Tregs maintain immune tolerance and laid the foundation for new treatments for autoimmune disease and cancer. At TRexBio, this biology forms the foundation of our drug discovery technologies. We study how Tregs behave in human tissue using our Deep Biology Platform, which identifies and characterizes the pathways that maintain or disrupt immune balance in health and disease. By understanding how Tregs function in specific tissues, we are developing a new generation of Treg-targeted medicines that are designed to restore immune balance. Our lead program, TRB-061, is a clinical-stage TNFR2 agonist that selectively expands Tregs in inflamed tissue. It is being studied in atopic dermatitis and has potential across a range of autoimmune and inflammatory diseases. Learn more about our approach: https://trex.bio Read more about the Nobel Prize in Physiology or Medicine 2025: https://lnkd.in/d862riYm #NobelPrize #Immunology #Tregs #AutoimmuneDisease #ClinicalTrials #DeepBiology

Members of the TRexBio management team will participate at two upcoming investor conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference taking place September 8-10, 2025, in New York City, and the Bank of America Healthcare Trailblazers Private Company Conference taking place September 17-18, 2025, in Boston. Our team is looking forward to one-on-one meetings and connecting with industry partners. Read more here: https://lnkd.in/eXmR7_eT #Tregs #immunology #DeepBiology #atopicdermatitis

We’re excited to announce that Ali Zarrin, PhD has been promoted to Chief Scientific Officer at TRexBio. Dr. Zarrin is an accomplished scientist who first joined TRexBio in 2019 and has led a team of scientists with the overall responsibility for target discovery, validation, and preclinical therapeutic development. Before TRexBio, Dr. Zarrin was in Early Research and Development at Genentech where he was instrumental in leading several transformational initiatives to advance multiple therapeutic programs covering diverse mechanistic pathways for inflammatory and autoimmune indications. “I am thrilled that Ali has been promoted to our leadership team as TRexBio’s CSO,” said Johnston Erwin, TRexBio’s Chief Executive Officer. “Under his scientific leadership, TRexBio developed our proprietary Deep Biology platform that led us to key insights into tissue-Treg biology. Our growing pipeline of Treg modulators and a first clinical study investigating TRB-061, our novel TNFR2 agonist, would not have been possible without his vision and dedication.”   #Tregs #immunology #DeepBiology #atopicdermatitis

The TRexBio team recently took a well-deserved break to get some sun together at our annual summer party. Our Culture Club organized minigolf and the inaugural “Regulatory T-Games” - Yes, we talk Tregs even at our parties! – for an afternoon in San Francisco. Cheers to the team as we sprint into the second half of the year with renewed focus on both our clinical and preclinical programs!   #Tregs #immunology #atopicdermatitis

TRexBio is excited to announce that we have initiated dosing of healthy volunteers in our first clinical trial for TRB-061, our novel TNFR2 agonist initially being developed for the treatment of atopic dermatitis.   "Despite approved treatments, many patients with atopic dermatitis experience inadequate relief of symptoms and troublesome side effects, highlighting the need for new mechanisms of action,” said Ariella Kelman MD, Chief Medical Officer of TRexBio. "TRB-061 is designed to modulate immune balance at the tissue level and may offer improved disease control and tolerability.”   Read more about today's announcement here: https://lnkd.in/eee4D-j3 #clinicaltrials #atopicdermatitis #immunology 

We are thrilled to announce the expansion of our Leadership Team with the addition of Ariella Kelman MD as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer! Their deep expertise in clinical development and financial strategy will be instrumental in advancing our TRB-061 program into the clinic. Read the press release: https://lnkd.in/eSrm254E

TRexBio is pleased to welcome Julie Gilmore, PhD, VP and Global Head of Lilly Gateway Labs (Eli Lilly and Company) to our Board of Directors!